Ticker
ABEO

Price
2.40
Stock movement down
-0.05 (-2.04%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Marktkapitalisierung
41.22M
Ent-Wert
58.84M
Preis/Umsatz
9.48
Preis/Buch
2.67
Div-Ertrag
-
Div Wachstum
-
Wachstumsjahre
-
FCF-Ausschüttung
-
Nachlaufendes KGV
-
Forward P/E
-
PEG
-
EPS-Wachstum
-
1 Jahr Rückkehr
727.59%
3-Jahres-Rendite
4.06%
5-Jahres-Rendite
-30.24%
10-Jahres-Rendite
-20.25%
Zuletzt aktualisiert: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
29. März 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
1. Dezember 2022

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABEO keine Dividenden ausschüttet
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
14. November 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. November 2022

iO Charts is a Seeking Alpha partner

BEWERTUNG

Bewertungskennzahlen

Loading...
Daten zu den Bewertungsverhältnissen
Nachlaufendes KGV-
Preis zu OCF-
Preis zu FCF-
Preis zu EBITDA-
EV zu EBITDA-

Bewertung (Umsatz/Buchwert)

Loading...
Bewertungsdaten (Umsatz/Buchwert)
Preis zu Umsatz9.48
Preis zum Buchen2.67
EV zu Verkäufen13.54
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. November 2022

iO Charts is a Seeking Alpha partner

Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
19. Oktober 2022

iO Charts is a Seeking Alpha partner

FINANZEN

Pro Aktie

Loading...
Angaben pro Aktie
Aktuelle Anzahl der Aktien17.18M
EPS (TTM)-13.28
FCF pro Aktie (TTM)-7.64

Gewinn- und Verlustrechnung

Loading...
Daten der Gewinn- und Verlustrechnung
Umsatz (TTM)4.35M
Bruttogewinn (TTM)4.00M
Betriebsergebnis (TTM)-84.63M
Reingewinn (TTM)-85.25M
EPS (TTM)-13.28
EPS (1 Jahr vorwärts)-1.79

Margen

Loading...
Daten zu den Margen
Bruttomarge (TTM)91.95%
Operative Marge (TTM)-1947.33%
Gewinnspanne (TTM)-1961.64%

Bilanz

Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Bilanzdaten
Bargeld5.73M
Nettoforderungen1.05M
Umlaufvermögen insgesamt25.50M
Goodwill0.00
Immaterielle Vermögenswerte0.00
Sachanlagen und Ausrüstung0.00
Gesamtvermögen38.76M
Verbindlichkeiten aus Lieferungen und Leistungen1.75M
Kurz-/kurzfristige langfristige Schulden8.29M
Kurzfristige Verbindlichkeiten insgesamt12.60M
Verbindlichkeiten insgesamt23.35M
Aktionärseigenkapital15.41M
Netto-Sachanlagen15.41M

Cashflow

Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Cashflow-Daten
Operativer Cashflow (TTM)-46.16M
Investitionsausgaben (TTM)2.91M
Freier Cashflow (TTM)-49.07M
Ausgeschüttete Dividenden (TTM)0.00

Finanzielle Erträge

Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Daten zu Finanzerträgen
Eigenkapitalrendite-553.12%
Kapitalrendite-219.95%
Rentabilität des investierten Kapitals-495.00%
Cash Return on Invested Capital-284.93%
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
4. Oktober 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. Oktober 2022

iO Charts is a Seeking Alpha partner

BESTANDSINFORMATIONEN

Aktienchart

Loading...
Daten zum Aktienkurs
Öffnen Sie2.46
Tageshöchststand2.49
Tägliches Tief2.38
Tägliches Volumen49K
Allzeithoch47188.00
1-Jahres-Analystenschätzung21.33
Beta1.25
EPS (TTM)-13.28
Dividende je Aktie-
Ex-Div-Datum22 Jul 2022
Nächstes Ergebnisdatum29 Mar 2023

Nachteiliges Potenzial

Loading...
Nachteilige potenzielle Daten
ABEOS&P500
Aktueller Preisrückgang vom Allzeithoch-99.99%-17.92%
Höchster Preisrückgang-100.00%-56.47%
Datum des höchsten Rückgangs17 Jun 20229 Mar 2009
Durchschnittlicher Rückgang vom Höchststand-92.06%-11.51%
Durchschnittliche Zeit bis zum neuen Höchststand406 days13 days
Maximale Zeit bis zum neuen Höchststand7600 days1805 days
The following slide deck was published by Abeona Therapeutics Inc.
17. August 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
11. August 2022

iO Charts is a Seeking Alpha partner

UNTERNEHMENSDATEN
ABEO (Abeona Therapeutics Inc) company logo
Marketcap
41.22M
Kategorie Marktkapitalisierung
Small-cap
Beschreibung
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Mitarbeiter
90
Investor Relations
-
SEC-Anmeldungen
CEO
Joao Siffert
Land
USA
Stadt
New York
Art des Bestands
Common stock
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
20. Juli 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
5. Juli 2022

iO Charts is a Seeking Alpha partner

DAS GESCHÄFT VERSTEHEN
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
19. Mai 2022

iO Charts is a Seeking Alpha partner

Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
17. Mai 2022

iO Charts is a Seeking Alpha partner

UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
We can readily understand why investors are attracted to unprofitable companies. For example, although...
31. März 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
29. März 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
24. März 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
16. März 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
14. März 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14. November 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8. November 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3. November 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3. November 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3. November 2022
Nächste Seite
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
17. Mai 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
13. Mai 2022

iO Charts is a Seeking Alpha partner